Literature DB >> 33669719

Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases.

Zhihong Hu1, Zenggang Pan2, Weina Chen3, Yang Shi4, Wei Wang5, Ji Yuan6, Endi Wang7, Shanxiang Zhang8, Habibe Kurt9, Brenda Mai1, Xiaohui Zhang10, Hui Liu5, Adan A Rios11, Hilary Y Ma12, Nghia D Nguyen1, L Jeffrey Medeiros5, Shimin Hu5.   

Abstract

Primary effusion lymphoma (PEL) is a rare type of large B-cell lymphoma associated with human herpesvirus 8 (HHV8) infection. Patients with PEL usually present with an effusion, but occasionally with an extracavitary mass. In this study, we reported a cohort of 70 patients with PEL: 67 men and 3 women with a median age of 46 years (range 26-91). Of these, 56 (80%) patients had human immunodeficiency virus (HIV) infection, eight were HIV-negative, and six had unknown HIV status. Nineteen (27%) patients had Kaposi sarcoma. Thirty-five (50%) patients presented with effusion only, 27 (39%) had an extracavitary mass or masses only, and eight (11%) had both effusion and extracavitary disease. The lymphoma cells showed plasmablastic, immunoblastic, or anaplastic morphology. All 70 (100%) cases were positive for HHV8. Compared with effusion-only PEL, patients with extracavitary-only PEL were younger (median age, 42 vs. 52 years, p = 0.001), more likely to be HIV-positive (88.9% vs. 68.6%, p = 0.06) and EBV-positive (76.9% vs. 51.9%, p = 0.06), and less often positive for CD45 (69.2% vs. 96.2%, p = 0.01), EMA (26.7% vs. 100%, p = 0.0005), and CD30 (60% vs. 81.5%, p = 0.09). Of 52 (50%) patients with clinical follow-up, 26 died after a median follow-up time of 40.0 months (range 0-96), and the median overall survival was 42.5 months. The median OS for patients with effusion-only and with extracavitary-only PEL were 30.0 and 37.9 months, respectively (p = 0.34), and patients with extracavitary-only PEL had a lower mortality rate at the time of last follow-up (35% vs. 61.5%, p = 0.07). The median OS for HIV-positive and HIV-negative patients were 42.5 and 6.8 months, respectively (p = 0.57), and they had a similar mortality rate of 50% at last follow-up. In conclusion, patients presenting with effusion-only versus extracavitary-only disease are associated with different clinicopathologic features. PEL is an aggressive lymphoma with a poor prognosis, regardless of extracavitary presentation or HIV status.

Entities:  

Keywords:  EBV; HHV8; HIV; Kaposi sarcoma; extracavitary variant; highly active antiretroviral therapy; primary effusion lymphoma

Year:  2021        PMID: 33669719     DOI: 10.3390/cancers13040878

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  [Primary effusion lymphoma with multisystemic extracavitary involvement in HIV negative diagnosed by autopsy]

Authors:  Martín Milanesio; Ana Victoria Sánchez; Luciana Guanchiale; Ruth Lía Kaplan
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-12-28

2.  Flow Cytometric Findings in Primary Effusion Lymphoma: A Report of Two Cases.

Authors:  Ahmad Alkhasawneh; Khaled S Mohamed; Ketav Desai; Reeba Omman; Brett Baskovich
Journal:  Cureus       Date:  2022-06-03

3.  Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo.

Authors:  Tomohiro Nishimori; Tomonori Higuchi; Yumiko Hashida; Takako Ujihara; Ayuko Taniguchi; Fumiya Ogasawara; Naoya Kitamura; Ichiro Murakami; Kensuke Kojima; Masanori Daibata
Journal:  Cancer Med       Date:  2021-11-24       Impact factor: 4.452

Review 4.  Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.

Authors:  Ilaria Cozzi; Giovanni Rossi; Emma Rullo; Valeria Ascoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

Review 5.  Primary Effusion Lymphoma: A Clinicopathologic Perspective.

Authors:  Diamone A Gathers; Emily Galloway; Katalin Kelemen; Allison Rosenthal; Sarah E Gibson; Javier Munoz
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

Review 6.  Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV.

Authors:  Chih-Yi Liu; Bo-Jung Chen; Shih-Sung Chuang
Journal:  Diagnostics (Basel)       Date:  2022-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.